To strategically aid Amyotrophic Lateral Sclerosis companies developing drugs for Amyotrophic Lateral Sclerosis, DelveInsight launched a report titled as “Amyotrophic Lateral Sclerosis Market Insight, Epidemiology And Market Forecast - 2034”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Amyotrophic Lateral Sclerosis market.
Get a Free sample for the Amyotrophic Lateral Sclerosis Market Report:
https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-market
Key Highlights from Amyotrophic Lateral Sclerosis market Report:
-
The Amyotrophic Lateral Sclerosis market size in the 7mm was valued ~1 billion in 2023 and is expected to grow with a significant CAGR during the forecast period (2020-2034).
-
In September 2025, Amylyx Pharmaceuticals announced that it has been allowed to proceed with submitting a New Drug Application (NDA) for its investigational ALS therapy, AMX0035, based on data from the Phase II CENTAUR trial, following recent discussions with the FDA. Earlier, in April 2021, the FDA had recommended conducting an additional Phase III study prior to approval, prompting the company to plan the global PHOENIX trial involving around 600 participants, expected to conclude in Q4 2023. However, the agency’s revised position suggests that AMX0035 could reach ALS patients sooner than initially anticipated. With promising clinical data and strong commercial potential, the therapy is expected to significantly impact the ALS treatment landscape, where effective options remain limited.
-
In August 2025, Coya Therapeutics announced that the FDA has accepted its Investigational New Drug (IND) application for COYA 302, an immunomodulatory biologic being developed for the treatment of amyotrophic lateral sclerosis (ALS).
-
In August 2025, Neurizon Therapeutics announced that manufacturing has commenced for the first registration batch of NUZ-001 tablets, its lead therapeutic candidate for amyotrophic lateral sclerosis (ALS). This milestone underpins upcoming pivotal studies, regulatory filings, and potential commercial production, representing a key step toward global market access.
-
In August 2025, Neurizon Therapeutics reported that the U.S. FDA is expected to issue a decision by October 3, 2025, regarding its Clinical Hold Complete Response (CHCR) submission for NUZ-001, the company’s lead investigational treatment for amyotrophic lateral sclerosis (ALS).
-
In July 2025, AB Science announced that its confirmatory Phase 3 trial of masitinib in amyotrophic lateral sclerosis (ALS), known as study AB23005, has been authorized by the initial group of European countries Spain, Greece, and Slovenia through the CTIS procedure, following EMA validation and earlier FDA clearance. This approval enables the company to initiate the registration study in both Europe and the United States.
-
In July 2025, Neurizon Therapeutics has submitted a formal response to the FDA to address the clinical hold placed on its Investigational New Drug (IND) application for NUZ-001, its lead therapeutic candidate for amyotrophic lateral sclerosis (ALS).
-
In July 2025, NKGen Biotech has received FDA authorization to implement an Expanded Access Program (EAP) allowing the use of its NK cell therapy, troculeucel, across multiple neurodegenerative disorders including Alzheimer’s, Parkinson’s, ALS, MSA, PSP, FTD, CBD, MS, and Lewy body dementia beyond its ongoing Phase 2a study in patients with moderate-stage Alzheimer’s disease.
-
In July 2025, Klotho Neurosciences announced that the FDA has granted Orphan Drug Designation to KLTO-202 (s-KL-AAV.myo), its secreted-Klotho gene therapy candidate, for the treatment of amyotrophic lateral sclerosis (ALS).
-
In June 2025, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced that the FDA has awarded Fast Track designation to AMX0114, an investigational antisense oligonucleotide designed to target calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS).
-
In May 2025, BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) has announced that it has received FDA approval to initiate its Phase 3b clinical trial evaluating NurOwn® for the treatment of amyotrophic lateral sclerosis (ALS).
-
In January 2025, The US Food and Drug Administration (FDA) has authorized Zydus Lifesciences to initiate a randomized Phase IIb clinical trial of Usnoflast, its oral NLRP3 inflammasome inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). This multi-center, double-blind, placebo-controlled study will evaluate the drug's safety, pharmacodynamics, efficacy, and pharmacokinetics in adult ALS patients.
-
In January 2025, The US Food and Drug Administration (FDA) has removed the clinical hold on Amylyx Pharmaceuticals’ Phase I trial of AMX0114 for amyotrophic lateral sclerosis (ALS). With the hold lifted, Amylyx can now initiate screening, enrollment, and dosing at US sites for the Phase I LUMINA study (NCT06665165). This multi-center, multiple ascending dose trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in 48 ALS patients. Participants will be randomized in a 3:1 ratio to receive either AMX0114 or a placebo via intrathecal injection every four weeks, for up to four doses.
-
The market size for ALS in the US was estimated at approximately USD 920 million in 2023, with expectations for growth throughout the forecast period (2024–2034).
-
RADICAVA is expected to be the top performer in the current ALS market, with projected revenue reaching USD 923 million in the US by 2034.
-
By 2034, Masitinib in combination with riluzole is projected to generate the highest revenue among emerging therapies, reaching USD 37 million in Japan.
-
Currently, ALS treatments include EXSERVAN (Riluzole oral film), RELYVRIO, QALSODY, RADICAVA (edaravone injection), RADICAVA ORS (edaravone oral suspension), NEUDEXTA, TIGLUTEK, and RILUTEK, along with other symptomatic therapies such as anti-epileptic drugs, opioids, NSAIDs, diuretics, SSRIs, and antidepressants.
-
In 2023, the US reported the highest number of ALS cases among the 7MM, with approximately 26,000 cases, and this number is expected to rise throughout the forecast period.
-
In 2023, Germany had the highest number of diagnosed prevalent ALS cases among the EU4 and the UK, whereas Spain had the fewest cases.
-
In 2023, the majority of ALS cases originated from the spinal site, with approximately 15,000 cases, followed by the bulbar site of onset. Other uncertain regions also contributed to the onset of ALS cases.
-
Estimates indicate that in Japan, ALS was most common in the 70-79 age group, followed by the 60-69 and 50-59 age groups.
-
Key Amyotrophic Lateral Sclerosis Companies: Amylyx Pharmaceuticals, Sanofi, Brainstorm Cell Therapeutics, AI Therapeutics, Ionis, Biogen, Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, and others
-
Key Amyotrophic Lateral Sclerosis Therapies: RELYVRIO, RILUTEK (Riluzole), Masitinib: AB Science, NurOwn (MSC-NTF cells), AIT-101 (LAM-002A), ION541, Engensis (VM202), SAR443820/DNL788, TPN-101, Latozinemab (AL001/GSK4527223), PrimeC, Tofersen (BIIB067), ION363, NurOwn (MSC-NTF cells), Reldesemtiv, Pegcetacoplan (APL-2), Gold Nanocrystals/CNM-Au8, AP-101, MN-166 (ibudilast), and others
Amyotrophic Lateral Sclerosis Overview:
The Amyotrophic Lateral Sclerosis market research report provides current treatment practices, emerging drugs, Amyotrophic Lateral Sclerosis market share of the individual therapies, current and forecasted Amyotrophic Lateral Sclerosis market Size from 2020 to 2034 segmented by seven major markets.
Lou Gehrig's disease, often known as amyotrophic lateral sclerosis (ALS), is a collection of uncommon neurological disorders primarily affecting the nerve cells (neurons) in charge of voluntary muscular movement. Movements like chewing, walking, and talking are produced by voluntary muscles. Since the illness is progressive, the symptoms worsen with time.
To Know in detail about the Amyotrophic Lateral Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Amyotrophic Lateral Sclerosis Market Forecast
Amyotrophic Lateral Sclerosis Epidemiology Insights:
The Amyotrophic Lateral Sclerosis epidemiology section offers insights into the past and present patient population affected by the disease, along with predicted trends across seven major countries. It assists in understanding the reasons behind current and anticipated trends by analyzing multiple studies and opinions from key experts.
-
In 2023, the US had the highest prevalence of ALS among the 7MM, with approximately 26,000 cases. This number is anticipated to rise throughout the forecast period.
-
In 2023, Germany had the highest number of diagnosed ALS cases among the EU4 and the UK, whereas Spain had the fewest cases.
-
The primary onset sites for ALS include the bulbar and spinal regions, along with other indeterminate areas. In 2023, spinal onset ALS had the highest number of cases, totaling 15,000, followed by bulbar onset.
-
The Amyotrophic Lateral Sclerosis epidemiology based on gender analyzed that males are more affected than females in case of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Epidemiology Segmentation:
-
Total Prevalence of Amyotrophic Lateral Sclerosis
-
Prevalent Cases of Amyotrophic Lateral Sclerosis by severity
-
Gender-specific Prevalence of Amyotrophic Lateral Sclerosis
-
Diagnosed Cases of Episodic and Chronic Amyotrophic Lateral Sclerosis
Download the report to understand which factors are driving Amyotrophic Lateral Sclerosis epidemiology trends @ Amyotrophic Lateral Sclerosis Epidemiology Forecast
Amyotrophic Lateral Sclerosis Drugs and Key Companies
-
RELYVRIO: Amylyx Pharmaceuticals
-
RILUTEK (Riluzole): Sanofi
-
Masitinib: AB Science
-
NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
-
AIT-101 (LAM-002A): AI Therapeutics
-
ION541: Ionis/ Biogen
-
Engensis (VM202): Helixmith
-
SAR443820/DNL788: Sanofi/Denali Therapeutics
-
TPN-101: Transposon Therapeutics
-
Latozinemab (AL001/GSK4527223): Alector/GSK
-
PrimeC: NeuroSense Therapeutics
-
Tofersen (BIIB067): Biogen/Ionis
-
ION363: Ionis Pharmaceuticals
-
NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
-
Reldesemtiv: Cytokinetics/Astellas Pharma
-
Pegcetacoplan (APL-2): Apellis Pharmaceuticals
-
Gold Nanocrystals/CNM-Au8: Clene Nanomedicine Biosciences
-
AP-101: AL-S Pharma
-
MN-166 (ibudilast): MediciNova
Discover more about therapies set to grab major Amyotrophic Lateral Sclerosis market share @ Amyotrophic Lateral Sclerosis Treatment Market
Amyotrophic Lateral Sclerosis Market Drivers
-
Rising prevalence of Amyotrophic Lateral Sclerosis and increasing global disease burden
-
Growing investment in neurodegenerative disease research and drug development
-
Advancements in gene therapy, RNA-based therapeutics, and precision medicine
-
Strong pipeline of emerging therapies and ongoing clinical trials
-
Increasing awareness and early diagnosis supported by improved diagnostic tools
-
Regulatory support and orphan drug designations accelerating approvals
-
Expansion of healthcare infrastructure and access to specialized neurological care
Amyotrophic Lateral Sclerosis Market Barriers
-
High cost of treatment and limited affordability in developing regions
-
Lack of curative therapies; most treatments offer only symptomatic relief or modest disease progression delay
-
Challenges in early and accurate diagnosis due to disease heterogeneity
-
Stringent regulatory requirements and high clinical trial failure rates
-
Limited understanding of disease pathophysiology
-
Reimbursement issues and restricted access to advanced therapies
-
Small patient population impacting large-scale commercial viability
Scope of the Amyotrophic Lateral Sclerosis Market Report:
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Amyotrophic Lateral Sclerosis Companies: Amylyx Pharmaceuticals, Sanofi, Brainstorm Cell Therapeutics, AI Therapeutics, Ionis, Biogen, Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, AI Therapeutics, and others, and others
-
Key Amyotrophic Lateral Sclerosis Therapies: RELYVRIO, RILUTEK (Riluzole), Masitinib: AB Science, NurOwn (MSC-NTF cells), AIT-101 (LAM-002A), ION541, Engensis (VM202), SAR443820/DNL788, TPN-101, Latozinemab (AL001/GSK4527223), PrimeC, Tofersen (BIIB067), ION363, NurOwn (MSC-NTF cells), Reldesemtiv, Pegcetacoplan (APL-2), Gold Nanocrystals/CNM-Au8, AP-101, MN-166 (ibudilast), and others
-
Amyotrophic Lateral Sclerosis Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and Amyotrophic Lateral Sclerosis emerging therapies
-
Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis market drivers and Amyotrophic Lateral Sclerosis market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Amyotrophic Lateral Sclerosis Unmet Needs, KOL’s views, Analyst’s views, Amyotrophic Lateral Sclerosis Market Access and Reimbursement
To know more about Amyotrophic Lateral Sclerosis companies working in the treatment market, visit @ Amyotrophic Lateral Sclerosis Clinical Trials and Therapeutic Assessment
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
